Amit J. Rushi is a distinguished leader in healthcare innovation with extensive experience and expertise in corporate strategy, digital health, and executive leadership. With a strong commitment to advancing healthcare through data and digital innovation, Amit has held key positions at major companies in the industry. He currently serves as the Chief Marketing & Partnerships Officer at RhythmScience, a comprehensive cardiac data platform company that enhances cardiology care. Additionally, Amit held the position of Chief Commercial Officer at Bodyport, a company tackling heart failure management with its FDA-cleared Cardiac Scale solution. He has also been the Vice President, Commercial & Product at Alio, a startup focused on remote monitoring solutions for vulnerable populations of Dialysis patients. Amit's impressive career also includes roles at renowned companies like Medtronic where he spent a decade leading product development, marketing, and informatics innovation departments and at Science37, a virtual clinical trial startup where he spearheaded business strategy and operations. Amit began his career at Valeant Pharmaceuticals, Amgen, and consulting for the Hospital, Health Systems, and Payer sectors. Amit earned both his MBA and MSIS degrees from the Questrom School of Business at Boston University and BS in business administration from the Marshall School of Business at the University of Southern California.
Farahnaz Forozan is a Clinical Ph.D., an industry veteran with over 24 years of experience in the life science industry & proven track record having contributed to the development, approval, and post-marketing launch of more than 15 marketed products and more than 30 global programs in various stages of clinical development. She is the Founder and President of a global, virtual consulting firm based on in Los Angeles that provides strategic and technical support to clients across the healthcare sector, including VCs, encompassing the therapeutics, diagnostics, & device sectors, globally (including Australia and Asia). She offers a spectrum of expertise & experiences pertaining to pharma, biotech, in vitro and companion diagnostics, medical device, clinical diagnostics, clinical trials and CRO/Central lab industries with specialized expertise in drug discovery & development, complex & comprehensive R&D/preclinical as well as clinical & translational, regulated laboratory build outs, implementing precision medicine, extensive global regulatory expertise, preclinical & clinical pipeline delivery from discovery through launch, particularly in oncology, & immuno-Oncology, neurology, autoimmune disorders, and microbiome. Farahnaz earned her Ph.D. through a joint program between the George Washington University & National Institutes of Health, National Human Genome Research Institute and obtained her clinical licensure in Los Angles after completing her postdoc at UCLA, while serving as Faculty at Cedar-Sinai Medical Center.
As the Academic and Corporate Business Development Lead at General Inception, I lean on my 20+ years of experience in bridging the gap between academia and industry, and turning cutting-edge research into novel and impactful products and services. My mission is to partner with inventors, entrepreneurs, and investors to ignite innovation and create transformational companies benefiting society and the environment.
I also serve as the Interim Chief Executive Officer at Regain BioMedicals, a startup developing a novel device to treat essential tremor, a debilitating condition that affects millions of people worldwide. I am responsible for leading the strategic direction, fundraising, and business development of the company, as well as overseeing the clinical trials and regulatory approvals of our patented technology.
I am passionate about bringing breakthrough research tools and biomedical solutions to the market, accelerating discoveries and improving patient outcomes.
Our tagline, HR that Makes a Difference™, defines what we do. It emphasizes that human resources is a key driver of growth and contributes to a business’s bottom line. This is what sets Insperity apart.
Insperity has a long history of improving the success equation of small and midsize businesses across the country – because when businesses succeed, communities prosper.
And in today’s changing business environment, it’s our privilege to take care of an organization’s most valuable asset: its people.
For over 28 years, Biocom California has helped move the life science industry forward with transformative resources that enable companies to make meaningful connections. Biocom California harnesses the collective power and experience of the most innovative and productive life science clusters in the world, with powerful advocacy and transformative programs to help companies in their quest to improve the human condition.
NexCore Group is a national healthcare real estate investment and development company that focuses on acquiring, developing, owning and managing healthcare facilities including medical office buildings, wellness facilities, ambulatory surgery centers, single and multi-specialty physician buildings, life sciences facilities, seniors housing communities and transitional rehabilitation centers. NexCore has completed $4.7 billion in healthcare real estate transactions throughout 29 states, developed and acquired over 14.3 million square feet of healthcare properties across the country and currently manages over $2.9 billion of healthcare facilities spanning 7.3 million square feet. The company has been recognized repeatedly as one of the Top Healthcare Real Estate Developers in the U.S. by Modern Healthcare and HREI.
HATCHspaces ®, LLC is a Los Angeles-based real estate development platform focused on simplifying the process of scientific innovation by creating purpose-built life sciences facilities for companies emerging from academic and incubator networks. With properties in various regional submarkets, HATCHspaces’® mission is to deliver the life science community state-of-the-art lab facilities at varying scales, allowing regions to retain early-stage bioscience and biotechnology start-ups emerging from research environments.
Wednesday, February 28, 2024
05:00 PM - 08:00 PM
The Capital Grille
3333 Bristol St, Costa Mesa, CA 92626